Online citations, reference lists, and bibliographies.
← Back to Search

Transcatheter Arterial Embolization With Zinostatin Stimalamer For Hepatocellular Carcinoma

T. Okusaka, S. Okada, H. Ueno, M. Ikeda, R. Iwata, H. Furukawa, K. Takayasu, N. Moriyama, T. Sato, Keiko Sato
Published 2002 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Zinostatin stimalamer (SMANCS) is a lipophilic intra-arterial chemotherapeutic agent for hepatocellular carcinoma (HCC). In our previous study, transcatheter arterial infusion chemotherapy using SMANCS for HCC showed a response rate of 20%. In an effort to obtain a superior anti-tumor effect against HCC, we conducted a phase II study of transcatheter arterial embolization (TAE) using SMANCS and gelatin sponge in 50 chemotherapy-naive patients with HCC. Four milligrams SMANCS plus 4 ml lipiodol emulsion was injected into the hepatic artery, followed by an injection of gelatin sponge. The responses were evaluated by computed tomography (CT) 1 month after treatment and thereafter every 3–4 months. One patient (2%) showed complete response and 15 patients (30%) had partial response resulting in an overall response rate of 32% (16/50; 95% confidence interval 19–45%). In 33 patients (66%), the disease remained stable, and 1 patient (2%) showed progressive disease. In 35 patients (70%), the rate of necrotic area to whole tumor was more than 50% according to the evaluation method using lipiodol accumulation in CT. The 1-, 3- and 5-year survival rates were 90, 55 and 19%, respectively. Grade 3 hematological toxicity was observed as thrombocytopenia in 2 patients (4%). Grade 3 and 4 non-hematological toxicity (liver dysfunction) occurred in 17 (34%) and 7 patients (14%), respectively. TAE using SMANCS, which was well tolerated, may be an effective treatment for advanced HCC.
This paper references
10.1038/bjc.1993.179
Augmentation of tumour delivery of macromolecular drugs with reduced bone marrow delivery by elevating blood pressure.
C. J. Li (1993)
10.2214/AJR.175.3.1750699
Comparison of CT findings with resected specimens after chemoembolization with iodized oil for hepatocellular carcinoma.
K. Takayasu (2000)
Tumoritropic and lymphotropic principles of macromolecular drugs.
H. Maeda (1989)
10.1007/BF01040499
Tailor-making of protein drugs by polymer conjugation for tumor targeting: A brief review on smancs
H. Maeda (1984)
Use of oily contrast medium for selective drug targeting to tumor: enhanced therapeutic effect and X-ray image.
K. Iwai (1984)
10.1007/978-1-4612-4380-9_25
Nonparametric Estimation from Incomplete Observations
E. L. Kaplan (1958)
10.1097/00000421-198212000-00014
Toxicity and response criteria of the Eastern Cooperative Oncology Group
M. Oken (1982)
10.1159/000012115
Evaluation of the Therapeutic Effect of Transcatheter Arterial Embolization for Hepatocellular Carcinoma
T. Okusaka (2000)
10.1007/s005350050360
Hepatic vascular side effects of styrene maleic acid neocarzinostatin in the treatment of hepatocellular carcinoma
K. Ikeda (2000)
10.1016/S0168-8278(98)80187-6
Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. Groupe CHC.
G. Pelletier (1998)
10.1016/0277-5379(83)90028-7
Effect of arterial administration of high-molecular-weight anticancer agent SMANCS with lipid lymphographic agent on hepatoma: a preliminary report.
T. Konno (1983)
10.1021/BC00017A001
Conjugates of anticancer agents and polymers: advantages of macromolecular therapeutics in vivo.
H. Maeda (1992)
10.1159/000011863
Transarterial Chemotherapy with Zinostatin Stimalamer for Hepatocellular Carcinoma
T. Okusaka (1998)
10.1148/RADIOLOGY.195.3.7754005
Unresectable hepatocellular carcinoma: analysis of prognostic factors in transcatheter management.
Y. Hatanaka (1995)
10.1148/RADIOLOGY.163.2.3031724
Hepatocellular carcinoma: treatment with intraarterial iodized oil with and without chemotherapeutic agents.
K. Takayasu (1987)
10.1002/HEP.510270617
Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: Results of a randomized, controlled trial in a single institution
J. Bruix (1998)
10.1016/0168-8278(90)90110-D
A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma.
G. Pelletier (1990)
10.1021/JM00382A012
Conjugation of poly(styrene-co-maleic acid) derivatives to the antitumor protein neocarzinostatin: pronounced improvements in pharmacological properties.
Hiroshi Maeda (1985)



This paper is referenced by
10.1007/s00535-009-0109-8
Transcatheter arterial infusion chemotherapy with cisplatin–lipiodol suspension in patients with hepatocellular carcinoma
M. Ikeda (2009)
10.1002/ANGE.201403036
Maßgeschneiderte Nanopartikel für den Wirkstofftransport in der Krebstherapie
Tianmeng Sun (2014)
10.1016/j.jconrel.2017.10.027
New molecular targets for functionalized nanosized drug delivery systems in personalized therapy for hepatocellular carcinoma
C. Turato (2017)
10.1007/s11604-013-0231-7
Antitumor effect of miriplatin-lipiodol suspension/emulsion using a VX2 liver tumor model
Yuki Tomozawa (2013)
10.1159/000076331
Transcatheter Arterial Chemotherapy with and without Embolization in Patients with Hepatocellular Carcinoma
M. Ikeda (2004)
10.1016/B978-1-4160-3256-4.50089-2
Embolization of Liver Tumors
C. Yoon (2007)
10.1148/RADIOL.2291021029
Transcatheter arterial chemoembolization with paclitaxel-lipiodol solution in rabbit VX2 liver tumor.
C. Yoon (2003)
10.1007/12_026
The EPR Effect and Polymeric Drugs: A Paradigm Shift for Cancer Chemotherapy in the 21st Century
H. Maeda (2005)
10.3390/cancers4010165
Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma in Japan
H. Nishikawa (2012)
10.1016/j.jhep.2009.09.004
Transarterial chemotherapy alone versus transarterial chemoembolization for hepatocellular carcinoma: a randomized phase III trial.
T. Okusaka (2009)
10.5958/2231-5713.2015.00008.2
A Review- Emerging Use of Nano-Based Carriers in Diagnosis and Treatment of Cancer-Novel Approaches
Yaqub Khan (2015)
10.1007/s00270-011-0172-4
Comparison of the Anti-tumor Effects of Two Platinum Agents (Miriplatin and Fine-Powder Cisplatin)
S. Watanabe (2011)
10.5649/JJPHCS.34.794
Adverse Events due to Cisplatin-Lipiodol^[○!R] Ultra-Fluide Suspension in Patients with Primary Hepatocellular Carcinoma
K. Miyazawa (2008)
10.2214/AJR.09.3308
Overall survival after transarterial lipiodol infusion chemotherapy with or without embolization for unresectable hepatocellular carcinoma: propensity score analysis.
K. Takayasu (2010)
10.3322/caac.21199
Nanooncology: The future of cancer diagnosis and therapy
A. Thakor (2013)
10.1016/j.addr.2011.04.002
Role of tumor vascular architecture in drug delivery.
A. Narang (2011)
10.1023/B:DRUG.0000011793.72775.d1
Phase II Trial of Intra-Arterial Chemotherapy using a Novel Lipophilic Platinum Derivative (SM-11355) in Patients with Hepatocellular Carcinoma
T. Okusaka (2004)
10.1002/anie.201403036
Engineered nanoparticles for drug delivery in cancer therapy.
T. Sun (2014)
10.1007/978-3-319-92067-2_32-1
Drug Delivery: Localized and Systemic Therapeutic Strategies with Polymer Systems
Scott Campbell (2019)
10.1046/j.1399-0012.2003.00055.x
Chemoembolization followed by orthotopic liver transplant for epithelioid hemangioendothelioma
S. S. St. Peter (2003)
10.3892/OL_00000161
Comparison of survival rates between patients treated with transcatheter arterial chemoembolization and hepatic resection for solitary hepatocellular carcinoma.
Y. Baba (2010)
Semantic Scholar Logo Some data provided by SemanticScholar